Insider Selling: Hemostemix Inc. (CVE:HEM) Director Sells 96,464 Shares of Stock

Hemostemix Inc. (CVE:HEM) Director Peter Alan Lacey sold 96,464 shares of Hemostemix stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of C$0.18, for a total value of C$16,881.20.

Hemostemix Price Performance

Hemostemix stock opened at C$0.18 on Friday. The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04. Hemostemix Inc. has a 52 week low of C$0.04 and a 52 week high of C$0.43. The stock has a market capitalization of C$26.23 million, a P/E ratio of -5.25 and a beta of 0.20. The stock has a fifty day moving average of C$0.21 and a 200-day moving average of C$0.12.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.